Ninebio

Ninebio is a clinical-stage Danish biotechnology company focused on developing innovative peptide-based therapies for metabolic disorders, particularly obesity and metabolic-associated steatohepatitis (MASH). The company was founded in 2021 by former Novo Nordisk executives and is headquartered at the BioInnovation Institute in Copenhagen. Its lead program, NB-01, is a long-acting dual agonist of the GLP-1 and glucagon receptors, aiming to provide superior weight loss and metabolic benefits compared to existing GLP-1 mono-therapies. Ninebio's approach combines deep expertise in incretin biology with advanced peptide engineering to create highly potent and stable therapeutic candidates. The company is supported by leading life science investors, including Novo Holdings, and aims to address the global obesity epidemic through differentiated multi-agonist peptides.